News

Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing
Skye’s Nimacimab shows promise in obesity treatment with lean mass preservation. Phase 2a results slated for 2025 could drive ...
Why Is Micro-Cap Artelo Biosciences Stock Trading Higher On Monday?
Artelo reports favorable Phase 1 results for its FABP5 inhibitor, showing strong safety data and dose-dependent absorption in ...
Investing.com India8d
Artelo Biosciences stock soars after positive first-in-human study results
Investing.com -- Artelo Biosciences Inc (NASDAQ: ARTL) stock surged over 100% following favorable results from its first-in-human study evaluating ART26.12, a novel inhibitor of Fatty Acid Binding ...
Yahoo Finance9d
Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain
By targeting FABP5, ART26.12 modulates endogenous lipid signaling molecules that exert analgesic effects through established pathways, including TRPV1, PPAR alpha, and cannabinoid receptors, with ...
Global Kratom Coalition Applauds FDA Action Against Hydroxie and Expects Broader Crackdown Against Synthetic Opioids Like 7
FDA action aligns with a growing chorus of scientists, public health experts, and advocates warning against the public health ...
IGC Pharma, Inc.: IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon
POTOMAC, MD / ACCESS Newswire / June 23, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced the addition of a new clinical trial site at Tekton Research in Yukon, Ok ...
Nature27d
New paths to pain relief - Nature Biotechnology
Feature Published: April 2000 New paths to pain relief Vicki Brower Nature Biotechnology 18, 387–391 (2000) Cite this article ...
The Marijuana Herald6d
Study: Minor Cannabinoids Like CBN and CBC Show Potent Anti-Cancer Effects in Breast Cancer Models
Researchers from the Universidade do Porto have identified promising anti-cancer properties in four lesser-known cannabinoids ...
Zacks Small Cap Research on MSN13d
MIRA Announces Positive Test Results from Acquisition
MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic ...